🦊/Investors

Epidarex Capital

Venture capitaloperating company · company profile

Bethesda · Pre-Seed–Series A · 12 people tracked

Also known as EPIDAREX CAPITAL MANAGEMENT LLC · EPIDAREX CAPITAL US

Find your way into Epidarex Capital

1,274 people in our graph share verified history with the Epidarex Capital team — schools, employers, funds. One of them is your warm intro.

Steve Murrayunlockedknows Kyparissia Sirinakis · together at Boston College (overlapped)
knows the team · via Coopers & Lybrand
knows the team · via University of Pennsylvania
×4knows the team · via Colgate University
×2knows the team · via University of Leeds
×2knows the team · via Cancerresearchuk
Fox Verdict
Sign up to see your fit

Investment thesis

Epidarex is a transatlantic early-stage venture capital firm that invests in and helps build breakthrough life science companies located in emerging innovation hubs. Led by a diverse team of early-stage investors, the firm positions itself as a trusted partner to founders and co-investors, leveraging deep scientific and industry networks to create value and drive shared success across its portfolio.

Source: firm website, verified Sep 15, 2026.

Stage
Pre-Seed–Series A
Check
$2.5M – $6.3M
HQ
Bethesda, Maryland, US
Leads rounds
Leads
Instruments
Equity
Founded
2010
AUM
$190.5M
VC funds
3
Tracked investments
40
Unicorns
1
Acquisitions
5

Team · 12 people

from curated & public directories
A. Sinclair Dunlop· Managing Partnerin
Peter Finan· General Partnerin

What they invest in

from 24 of 40 portfolio companies

Biotech ×21Healthtech ×15Medical Devices ×8Deep Tech ×3AI & Machine Learning ×2Digital Health ×2Longevity ×2Impact & Social Good ×1

HQs:United States×9United Kingdom×5Germany×1

Investments · 40 tracked

founders shown can be your intro path

By year:2022 · 22020 · 12016 · 12015 · 15 dated

Harness Therapeutics Ltdharnesstx.comin✓ verified

Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.

BiotechHealthtech

Jan Thirkettle(CEO Director)in

Co-investorsOno Venture Investment, Inc.Dementia Discovery FundSV Health Investors

Lunac Therapeuticslunactherapeutics.com✓ verified

LUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk.

BiotechHealthtechMedical DevicesLeeds, GB

Professor Helen Philippou(Scientific Founder)Dr. Richard Foster(Scientific Founder)

Macomicsmacomics.comin✓ verified

Macomics is a drug discovery company developing therapies that target macrophage activity for diseases with limited or ineffective treatment options.

BiotechLongevity

Co-investorsScottish Enterprise

Nyra Medicalnyramedical.comin𝕏Nov 2022✓ verified

Nyra Medical develops the CARLEN (Cardiac Leaflet Enhancer) system, a transcatheter single-leaflet device for repairing functional mitral regurgitation while preserving native valve function.

BiotechHealthtechMedical DevicesAtlanta, US

Dr. Murali Padala(Founder)Dr. Eric Sarin(Founder, Director)Dr. Kirthana Suresh(Founder)Sai Muralidhar Padala(Executive Officer, Director)Lori Chmura(CEO)inGowri Raman(Director)

Co-investorsBroadview VenturesVensana CapitalGRA Venture

Theolyticstheolytics.com✓ verified

Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.

BiotechHealthtech

Co-investorsOxford Science EnterprisesSound BioventuresTaiho Ventures, LLCM Ventures

Confluence Life SciencesinApr 2016acquired by Aclaris Therapeutics

Technology-focused company on rational drug design for cancer and chronic inflammatory diseases (acquired by Aclaris Therapeutics in August 2017).

HealthtechSaint Louis, US

Jennifer Bohnert(Executive Officer)Walter Smith(Executive Officer, Director)Joseph Monahan(Executive Officer, Director)in

BoardDaniel Janiak(Director)Charles Bolten(Director)Thomas Smart(Director)

Board seatKyparissia Sirinakis· per SEC Form D

Slate Bioslatebio.cominDec 2020

Slate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases.

BiotechDigital HealthMedical DevicesCharlottesville, US

Robert Creeden(Director)Kurt Woerpel(Executive Officer)Andrew J Krouse(Executive Officer, Director)

Board seatKyparissia Sirinakis· per SEC Form D

Co-investorsVTC Ventures

Clyde Biosciences Cardiomyocyte Assayclydebio.com

Clyde Biosciences is a contract research organization offering predictive cardiac safety and efficacy testing using human iPSC-derived cardiomyocyte models, aimed at pharmaceutical and biotech teams assessing cardiotoxicity for clinical translation.

BiotechDeep TechHealthtech

Godfrey Smith(Chief Scientific Officer and Co-Founder)Francis Burton(Head of Software and Modeling & Co-Founder)Richard Henderson(Chief Executive Officer)Mark Bryant(Chief Business Officer)

Curve Therapeuticscurvetx.comin

Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets.

AI & Machine LearningBiotech

Co-investorsPfizer Venture InvestmentsColumbus Venture Partners

Dunaddunadtx.comin

Dunad Therapeutics is a biotech company developing oral small-molecule medicines using a covalent chemistry discovery platform to target neurodegenerative diseases such as ALS, Parkinson's disease, and FTD.

BiotechDeep TechCambridge, GB

Pearl Huang(President & CEO)inStephen Huhn(CMO)

Co-investorsBGVAlpha Wave Global

Edinburgh Molecular Imagingemimaging.com

University of Edinburgh spin-out clinical-phase biotech developing C-Met molecular targeting technology for cancer radiotherapy and imaging.

Co-investorsScottish Investment Bank

Enterprise Therapeuticsenterprisetherapeutics.comin𝕏

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.

BiotechHealthtechBrighton, GB

John Ford(Co-founder)inMartin Gosling(Founder)in

Co-investorsVersant Ventures

Epsilogenepsilogen.comin

Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.

BiotechHealthtech

Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)

Co-investors3B Future Health FundAlbionVCGlobal BioAccess FundNovartis Venture FundUCL Technology FundBioGeneration Ventures

Kidneykidney.orgin

The National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services.

HealthtechImpact & Social Good

Co-investorsYsios CapitalBioGeneration VenturesRoche Venture FundScottish National Investment BankSofinnova Partners

Kodikaz websitekodikaz.comin𝕏

Kodikaz develops Zip-Code, a non-viral cell-specific delivery platform for gene therapy applications, particularly focused on oncology and cancer treatments.

AI & Machine LearningBiotechMedical DevicesAtlanta, US

Anthony Johnson(Co-Founder & CEO)inDr. Leon Bernal-Mizrachi(Co-Founder, CSO)in

Co-investorsGRA VentureIllumina Ventures

Lariotxlariotx.com

Lario Therapeutics develops first-in-class precision medicines aimed at disease-modifying treatments for severe neurological disorders, including developmental and epileptic encephalopathies and Parkinson's disease.

BiotechDeep Tech

Leucidleucid.com

Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors.

BiotechHealthtechLondon, GB

John Maher(Founder)

Co-investorsSofinnova PartnersVulpes Investment Management

Libra Therapeuticslibratherapeutics.comin𝕏

Libra Therapeutics develops small molecule therapeutics targeting lysosomal function and autophagy to treat neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Huntington's disease.

BiotechLongevityMedical Devices

Dr. Gill(Chief Scientific Officer)

Co-investorsDolby Family Ventures

Mironidmironid.comin𝕏

Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.

BiotechMedical Devices

Adele Rowley(Chief Scientific Officer)in

Co-investorsRoche Venture FundSofinnova PartnersBioGeneration VenturesScottish National Investment Bank

Nodtheranodthera.comin𝕏

NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.

BiotechHealthtech

Geoff McDonough(Executive Team / Board)inChris Guiffre(Executive Team)inAlan P. Watt(Executive Team)inJyothis George(Chief Medical Officer)inNick Clarke(Executive Team)in

Co-investors5AM VenturesF-Prime CapitalSanofi VenturesSofinnova Partners

Rapidpulsemedrapidpulsemed.com

RapidPulse Medical is an investor relations page showcasing multiple healthcare-focused investment firms and incubators that back medical device and healthcare technology companies.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsBroadview VenturesHatteras Venture Partners

Ryme Medicalrymemedical.com

Ryme Medical develops a catheter-based therapy to treat chronic obstructive pulmonary disease (COPD) by reducing airway inflammation and improving patient outcomes.

BiotechHealthtechMedical DevicesMountain View, US

Co-investorsSeroba Life Sciences

Topas Therapeuticstopas-therapeutics.comin

Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases.

BiotechHealthtech

Hugo Fry(Chief Executive Officer)inChristian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)in

Co-investorsEMBL VenturesBoehringer Ingelheim Venture FundGimvBioMedPartners

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Harpoon Medical, Inc.AdorxAdoRx TherapeuticsApellis PharmaceuticalsCaldan TherapeuticsClyde BiosciencesEdinimageHarnessKodikaz Therapeutic SolutionsKynos TherapeuticsKynostxLario TherapeuticsRapidPulseSIRAKOSSSyntheon 2.0

Exits · 5

5 acquisitions

Confluence Life Sciencesacq. by Aclaris TherapeuticsHarpoon Medical, Inc.acq. by Edwards LifesciencesApellis Pharmaceuticalsacq. by BiogenKynos Therapeuticsacq. by Dr. Falk Pharma GmbHSIRAKOSSacq. by OssDsign

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has Epidarex Capital made?
Epidarex Capital has 40 tracked investments, 5 of which have exited.
What stage does Epidarex Capital invest at?
Epidarex Capital invests at the Pre-Seed, Seed, Series A stages.
What is Epidarex Capital's typical check size?
Epidarex Capital typically writes checks of $2.5M – $6.3M.
What sectors does Epidarex Capital focus on?
Epidarex Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Epidarex Capital located?
Epidarex Capital is headquartered in Bethesda, US.
Does Epidarex Capital lead rounds?
Yes, Epidarex Capital leads investment rounds.
Who does Epidarex Capital co-invest with?
Epidarex Capital most often shares deals with Broadview Ventures, EMBL Ventures, F-Prime Capital, among 32 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Dr Peter Finan, BIA Board Member, Partner, Epidarex Capital on SVB collapse

BioIndustry Association - BIA · Peter Finan

Similar investors

Featured in lists